Surmodics Acquires Vetex Medical Limited

Surmodics Acquires Alta Biomed to Expand Medical Device Coating and Testing Capabilities

October 2, 2026

Medical Devices

Surmodics acquired the business of Alta Biomed to expand its portfolio of hemocompatible and biocompatible surface technologies, including the proprietary PzF thin-film surface modification technology. The deal also adds specialized analytical testing capabilities for blood- and tissue-contacting medical devices at Alta Biomed’s Carlsbad, California facility.

Endologix Acquires Pounce Thrombectomy System From Surmodics

May 20, 2026

Medical Devices

Endologix, a privately held medical device company, announced it will acquire the Pounce Thrombectomy System from Surmodics. The FDA-cleared, fully mechanical peripheral thrombectomy platform is intended to complement Endologix’s existing vascular intervention portfolio and expand the continuum of care for patients with peripheral vascular disease.

Medtronic to Acquire Scientia Vascular

March 10, 2026

Medical Devices

Medtronic entered into a definitive agreement to acquire Scientia Vascular in a $550 million deal, with customary adjustments and potential earn-out/milestone payments. The acquisition combines Scientia’s neurovascular access devices (guidewires and catheters) with Medtronic’s existing neurovascular therapeutic portfolio to support faster and more reliable treatment for complex stroke cases.

Haemonetics Acquires Vivasure Medical

January 11, 2026

Medical Devices

Haemonetics Corporation has acquired Galway-based Vivasure Medical in a transaction valued at up to €185 million, consisting of an upfront €100 million payment plus up to €85 million in contingent milestone payments. The acquisition adds Vivasure's PerQseal Elite fully bioabsorbable vascular closure system to Haemonetics' large-bore closure portfolio; Vivasure has CE Mark approvals and has submitted a PMA to the U.S. FDA.

GTCR Affiliate Acquires Surmodics, Inc.

November 10, 2025

Medical Devices

Surmodics announced that a U.S. district court denied the FTC and certain state regulators’ request for a preliminary injunction to block the company’s proposed acquisition by an affiliate of GTCR. Surmodics said the merger remains subject to a temporary restraining order and customary closing conditions, with the company expecting to move toward closing promptly.

GTCR to Acquire Surmodics for $43.00 per Share; Equity Value Approximately $627M

May 29, 2024

Medical Devices

GTCR, a leading private equity firm, will acquire Surmodics, a Minnesota-based medical device and in vitro diagnostic technologies company, for $43.00 per share in cash, implying an approximate equity value of $627 million. The transaction, unanimously approved by Surmodics' board, is expected to close in the second half of 2024 and will take Surmodics private following customary regulatory and shareholder approvals.